Combined Biomarkers for Early Alzheimer Disease Diagnosis

Borroni, Barbara; Premi, Enrico; Luca, Monica Di; Padovani, Alessandro

doi:10.2174/092986707780598005

Cited by 32 publications

(18 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been suggested that measuring a single biomarker will not be sufficient to identify preclinical AD [70,71]. Indeed, a recent study showed the power of combining multiple biomarkers, demonstrating that such a combination of 18 biomarkers could predict the progression to AD among 22 MCI individuals with 90% accuracy [72].…”

Section: Discussionmentioning

confidence: 99%

Systemic Inflammation Is Associated with MCI and Its Subtypes: The Sydney Memory and Aging Study

Trollor¹,

Smith

Baune

et al. 2010

Dement Geriatr Cogn Disord

108

View full text Add to dashboard Cite

Background/Aims: Raised low-grade systemic inflammation has been associated with dementia, and preliminary studies suggest an association with mild cognitive impairment (MCI). This study examines the relationship between systemic inflammation and MCI subtypes. Methods: We measured the inflammatory markers C-reactive protein, interleukins (IL)-1β, -6, -8, -10 and -12, plasminogen activator inhibitor-1 (PAI-1), serum amyloid A (SAA), tumor necrosis factor-α (TNF-α) and vascular adhesion molecule-1 (VCAM-1) in the Sydney Memory and Ageing Study (MAS) cohort, a longitudinal study of 1,037 Australians aged 70–90 years. Results: After adjusting for possible confounding variables, levels of TNF-α and SAA were higher in participants with MCI compared to cognitively normal individuals, and some sex differences were apparent. Nonamnestic multiple domain MCI was associated with higher levels of IL-1β and IL-12, TNF-α and SAA compared to cognitively normal, amnestic MCI (single and multiple domain) and nonamnestic single domain MCI. PAI-1 levels were higher in cognitively normal and nonamnestic multiple domain MCI than in amnestic multiple domain MCI. Conclusion: Our findings suggest an association between specific inflammatory markers and MCI subtypes, highlight sex differences in the association with MCI, and point to a discrete impact of systemic inflammation on cognition.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic Inflammation Is Associated with MCI and Its Subtypes: The Sydney Memory and Aging Study

Trollor¹,

Smith

Baune

et al. 2010

Dement Geriatr Cogn Disord

108

View full text Add to dashboard Cite

show abstract

“…Many authors consider mild cognitive impairment (MCI) as the most important risk factor in the development of AD [3]. Therefore, 40-60% of patients with MCI develop AD in the five years following diagnosis of MCI [2], even though many others have a stable form of memory alteration.…”

Section: Introductionmentioning

confidence: 99%

Biomarkers of Alzheimer′s Disease in the Cerebrospinal Fluid of Spanish Patients With Mild Cognitive Impairment

et al. 2011

View full text Add to dashboard Cite

The study of biomarkers in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) is a technique used with increasing frequency in the early diagnosis of Alzheimers disease (AD). Our objectiv was to gain an own experience while evaluating the reliability, sensitivity, and reproducibility of this technique in Spanish patients. Thirty-seven patients with MCI and twenty-four control subjects were studied by means of AD biomarker analysis in CSF. xMAP Luminex and INNO-BIA Alzbio3 reagents of Innogenetics were used. The study variables assessed were levels of Aβ(1-42), T-tau and P-tau(181p) proteins as well as the ratios of T-tau/Aβ(1-42) and P-tau(181p)/Aβ(1-42). Samples from nineteen patients were examined twice. Intra-class correlation coefficients for the three biomarkers used showed values higher than 0.95. We observed significant differences between the control group and the MCI groups. In the 6 months following lumbar puncture (LP), eleven (29%) patients with MCI developed AD. These patients showed significant lower levels in Aβ(1-42) protein (276.35 ± 78 vs. 367.13 ± 123.49, P < 0.03) and higher ratios (T-tau/Aβ(1-42) [0.38 ± 0.2 vs. 0.22 ± 0.14, P < 0.01] and P-tau(181p)/Aβ(1-42) [0.27 ± 0.13 vs. 0.16 ± 0.1, P < 0.008]) to those in the same group who remained stable. We obtained similar results to those in the most recent reliable literature with our ROC curves, especially with our P-tau(181p) values and T-tau/Aβ(1-42) ratio in order to differentiate between control and AD groups. Our experience showed that the analysis of CSF-AD biomarkers in patients with MCI is reliable, sensitive and reproducible. In our knowledge, this is the first experience in Spanish patients.

show abstract

“…Muchos autores consideran el DCL como el factor de riesgo más importante para desarrollar EA 10 . Así, el 40-60% de los pacientes con DCL desarrollan EA durante los siguientes 5 años 11 , aunque muchos otros tienen una forma estable de alteración de la memoria.…”

Section: Introductionunclassified

Análisis Multiplex de citoquinas intratecales en pacientes con deterioro cognitivo leve

Rodríguez-Borja

Monge-Argilés

Soriano-Terol

et al. 2011

Revista del Laboratorio Clínico

View full text Add to dashboard Cite

Combined Biomarkers for Early Alzheimer Disease Diagnosis

Cited by 32 publications

References 71 publications

Systemic Inflammation Is Associated with MCI and Its Subtypes: The Sydney Memory and Aging Study

Systemic Inflammation Is Associated with MCI and Its Subtypes: The Sydney Memory and Aging Study

Biomarkers of Alzheimer′s Disease in the Cerebrospinal Fluid of Spanish Patients With Mild Cognitive Impairment

Análisis Multiplex de citoquinas intratecales en pacientes con deterioro cognitivo leve

Contact Info

Product

Resources

About